The Rett Syndrome Research Trust Funds Herophilus’ Rett Syndrome Lead Candidate Studies
SAN FRANCISCO--(BUSINESS WIRE)-- #drugdiscovery--Herophilus announced today that in vivo studies underway of its lead candidate HRP-12975 are funded in part by the Rett Syndrome Research Trust (RSRT). HRP-12975 is the first small molecule therapy for Rett Syndrome with the potential to reverse the root cause of the disease, MECP2 deficiency....
